Status and phase
Conditions
Treatments
About
SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced solid tumor patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Pathologically confirmed solid tumor and failed from all standard treatment
Eastern Cooperative Oncology Group (ECOG) performance status: 0-1
Life expectancy ≥ 3 months
Adequate function of major organs, meaning the following criteria should be met within 14 days before randomization:
Good compliance of patient by physician's judgement
Signed and dated informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal